WorldPharmaNews
  • Home
  • Business
  • Research
  • Jobs
  • Events
  • Regulatory
AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

www.astrazeneca.com

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets 07 May 2018
Lokelma approved in the EU for the treatment of adults with hyperkalaemia 22 March 2018
New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors 14 March 2018
MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics 28 February 2018
Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease 07 February 2018
AstraZeneca listed as one of the world's top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage 23 January 2018
New research paper shows that AstraZeneca has achieved greater than four-fold improvement in R&D productivity 19 January 2018
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer 18 December 2017
AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China 27 November 2017
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma 15 November 2017
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
  • AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
  • FDA approves Pfizer's biosimilar, ABRILADAâ„¢ (adalimumab-afzb) for multiple inflammatory conditions
  • Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
  • Bayer selects Pharmaron as partner organization

Research & Development

  • The gut may be involved in the development of multiple sclerosis
  • Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer
  • Investigational drugs reduce risk of death from Ebola virus disease
  • Pharmacist-led interventions may help prevent cardiovascular disease
  • A protein tag to study the immune system
  • Industry executives: Profits drive rising prices for MS drugs
  • Artificial Intelligence algorithm can learn the laws of quantum mechanics and speed up drug delivery

Conferences & Events

  • Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
  • SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
  • SMi's 4th Annual 3D Cell Culture
  • Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
  • RNA Therapeutics Conference and Focus Day
  • CPhI Worldwide announces the winners of the 16th Pharma Awards
  • CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023

Regulatory Affairs

  • FDA approves first generics of Gilenya
  • FDA approves novel treatment to target abnormality in sickle cell disease
  • FDA approves first treatment for inherited rare disease
  • FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
  • FDA approves first therapy to treat patients with rare blood disorder
  1. You are here:  
  2. Home
  3. AstraZeneca

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2006 - 2017. All Rights Reserved. WORLD PHARMA JOBS | PharmaNews.eu | eHealthNews.eu | (HEALTH IT) SPACE